Celltrion Launches Remsima IV Liquid Formulation, Securing New Competitive Edge in Infliximab Market
Early Success with National Tenders in Norway and Denmark
Exclusive Holder of the World's Only Infliximab Liquid Formulation
"We Will Continue to Innovate Biosimilar Products"
Celltrion has launched the liquid formulation of 'Remsima' (active ingredient: infliximab) in Europe, aiming to strengthen its leadership in the infliximab market. The infliximab liquid formulation is a product uniquely held and patented by Celltrion worldwide.
According to Celltrion on March 11, its Northern Europe subsidiary has secured infliximab national tenders in Denmark and Norway with the Remsima intravenous (IV) liquid formulation. Since obtaining European approval for Remsima IV liquid formulation in November last year, the local subsidiary has participated in major national tenders.
In Norway, sales began immediately after winning the tender, and Celltrion is scheduled to supply the product until January 2028. The company expects to secure approximately 35% market share in the Norwegian infliximab IV market through this deal.
The Remsima liquid formulation expands choices for healthcare providers by reflecting medical field needs, in addition to the existing Remsima IV (100mg lyophilized formulation) and Remsima SC (subcutaneous injection formulation). European healthcare institutions have consistently demanded high-volume liquid formulations to improve storage and management efficiency while reducing the complexity of the preparation process.
The liquid formulation can reduce preparation time by approximately 50% compared to the lyophilized form and lower labor and consumable costs incurred during the administration process by about 20%. Storage space and associated fees can also be reduced by up to 70%. Celltrion believes these advantages will serve as new competitive strengths for Remsima in Europe, where tender-based procurement is significant.
Celltrion has filed for patents on the Remsima liquid formulation and has completed patent registrations in most countries, including the five major European markets (EU5) such as the United Kingdom, Germany, and France. Since Remsima is the only infliximab available in a liquid formulation, its unique product competitiveness is expected to further solidify its influence in the infliximab market. Celltrion remains the only company globally to offer the full range of infliximab IV (lyophilized and liquid) and SC formulations.
Starting with Northern Europe, Celltrion plans to expand the launch of the Remsima liquid formulation across Europe this year, including France, the Netherlands, and the Czech Republic, to further consolidate its leadership in the infliximab market. According to the pharmaceutical market research firm IQVIA, as of the third quarter of last year, the Remsima product line maintained its top position in the European infliximab market with a 68% share of prescriptions.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Baek Seungdoo, Head of Celltrion's Northern Europe subsidiary, stated, "We will continue to focus on field-oriented sales and marketing activities to provide better options for European patients and healthcare professionals, striving to further expand prescriptions."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.